vTv Therapeutics (VTVT) Receivables - Net (2015 - 2024)
vTv Therapeutics (VTVT) posted Receivables - Net of $62000.0 for Q4 2024, down 74.38% sequentially from $242000.0 in Q3 2024, and down 39.22% YoY from $102000.0 in Q1 2024.
vTv Therapeutics (VTVT) Receivables - Net (2015 - 2024) Analysis & Trends
vTv Therapeutics has reported Receivables - Net for 10 years, with the latest figure at $62000.0 in Q4 2024.
- Quarterly Receivables - Net fell 39.22% year-over-year to $62000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $62000.0 (down 39.22% YoY) and the FY2024 annual result came in at $62000.0, down 39.22% from the prior year.
- Receivables - Net declined to $62000.0 in Q4 2024 per VTVT's latest filing, from $242000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $12.5 million in Q2 2022 and troughed at $2000.0 in Q1 2021.
- A 5-year average of $3.1 million and a median of $173000.0 in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2023 and 2024: Receivables - Net surged 21829.82% in 2023, then sank 97.55% in 2024.
- Over 5 years, Receivables - Net stood at $158000.0 in 2020, then tumbled by 63.92% to $57000.0 in 2021, then jumped by 203.51% to $173000.0 in 2022, then plunged by 41.04% to $102000.0 in 2023, then sank by 39.22% to $62000.0 in 2024.
- According to Business Quant data, Receivables - Net over the past three periods registered $62000.0, $242000.0, and $306000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | vTv Therapeutics | 373.77 Mn | 373.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 62,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Sep 30, 2024 | 242,000.00 |
| Sep 30, 2024 | 242,000.00 |
| Jun 30, 2024 | 306,000.00 |
| Jun 30, 2024 | 306,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Jun 30, 2023 | 12.50 Mn |
| Jun 30, 2023 | 12.50 Mn |
| Mar 31, 2023 | 12.50 Mn |
| Mar 31, 2023 | 12.50 Mn |
| Dec 31, 2022 | 173,000.00 |
| Dec 31, 2022 | 173,000.00 |
| Sep 30, 2022 | 12.50 Mn |
| Sep 30, 2022 | 12.50 Mn |
| Jun 30, 2022 | 12.50 Mn |
| Jun 30, 2022 | 12.50 Mn |